Amgen Inc. stock (US0311621009): Shares open lower in New York

Amgen shares traded lower on the Nasdaq on 06/01/2026, while MarketBeat showed a $355.19 consensus target and a Hold rating snapshot.

Amgen shares opened lower on Monday on the Nasdaq, with MarketBeat citing an opening price of $336.79 and a 12-month range of $267.83 to $391.29 on 06/01/2026. The same screen showed an average rating of Hold and a consensus target price of $355.19, keeping the US-listed biotech in focus for investors following the United States market.

The stock's move also matters for the domestic benchmark backdrop because Amgen is a Nasdaq-listed member of the U.S. large-cap healthcare universe, and its latest quoted level sat below the consensus target shown in the same market snapshot on 06/01/2026. In Germany, the shares also appeared in U.S. dollar terms on market-monitoring pages during the session, offering a secondary reference point for European readers even though the primary listing remains in New York.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, and other global pharmaceutical markets
• Key revenue drivers: Prescription medicines and biologics
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen develops and sells biologic medicines, with revenue concentrated in specialty therapies marketed across the United States and other major healthcare markets.

What banks and research houses say about Amgen Inc.

MarketBeat's daily snapshot on 06/01/2026 showed an average rating of Hold and a consensus target price of USD 355.19 for Amgen, based on the site's compiled analyst data. The same page also listed the stock's 12-month range and opening price, giving readers a quick cross-check between sentiment and the current quote.

That combination of a Hold call and a target above the latest opening print suggests analysts still see valuation support, even after the session's softer start. For U.S. investors, the key reference remains the Nasdaq listing, while the market watch pages provide the most accessible same-day read-through on coverage and price positioning.

Conclusion

Monday's opening move kept Amgen in line with broader U.S. healthcare market attention, with the Nasdaq quote and MarketBeat consensus offering the clearest same-day read. The analyst snapshot remains the more important context layer today because it frames the share price against a consensus target above the latest opening level.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.